SmartHarvest Portfolios LLC Takes $751,000 Position in Astrazeneca Plc $AZN

SmartHarvest Portfolios LLC acquired a new stake in shares of Astrazeneca Plc (NYSE:AZN) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 4,278 shares of the company’s stock, valued at approximately $751,000.

A number of other institutional investors have also recently added to or reduced their stakes in AZN. Triumph Capital Management acquired a new position in Astrazeneca during the 3rd quarter valued at about $25,000. Bangor Savings Bank raised its stake in shares of Astrazeneca by 102.7% during the fourth quarter. Bangor Savings Bank now owns 304 shares of the company’s stock valued at $28,000 after purchasing an additional 154 shares in the last quarter. Eagle Bay Advisors LLC acquired a new stake in Astrazeneca in the fourth quarter worth about $30,000. YANKCOM Partnership bought a new position in Astrazeneca in the 4th quarter valued at about $31,000. Finally, TFC Financial Management Inc. grew its position in Astrazeneca by 3,350.0% in the 4th quarter. TFC Financial Management Inc. now owns 345 shares of the company’s stock valued at $32,000 after buying an additional 335 shares in the last quarter. 20.35% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

AZN has been the subject of several recent analyst reports. Barclays reiterated a “buy” rating on shares of Astrazeneca in a report on Monday, June 1st. TD Cowen restated a “buy” rating on shares of Astrazeneca in a research report on Wednesday, March 18th. Wall Street Zen raised Astrazeneca from a “hold” rating to a “buy” rating in a research note on Saturday, May 2nd. Deutsche Bank Aktiengesellschaft reiterated a “sell” rating on shares of Astrazeneca in a research report on Tuesday. Finally, DZ Bank raised Astrazeneca from a “neutral” rating to a “buy” rating in a research note on Wednesday, April 29th. Twelve equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Astrazeneca has an average rating of “Moderate Buy” and an average price target of $205.33.

Astrazeneca Price Performance

AZN stock opened at $182.48 on Friday. Astrazeneca Plc has a one year low of $137.23 and a one year high of $212.71. The firm has a 50-day moving average of $189.75 and a two-hundred day moving average of $185.85. The firm has a market capitalization of $283.00 billion, a PE ratio of 27.40, a P/E/G ratio of 1.56 and a beta of 0.25. The company has a current ratio of 0.91, a quick ratio of 0.71 and a debt-to-equity ratio of 0.52.

Astrazeneca (NYSE:AZN) last issued its quarterly earnings results on Wednesday, April 29th. The company reported $2.58 EPS for the quarter, beating the consensus estimate of $2.52 by $0.06. The business had revenue of $15.29 billion during the quarter, compared to the consensus estimate of $14.93 billion. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%. On average, analysts forecast that Astrazeneca Plc will post 9.37 earnings per share for the current year.

Astrazeneca Company Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.